



## **BIOGRAPHY**

**Thomas F. Soriano**  
**President and Chief Executive Officer**  
**DOCRO, Inc.**  
**Telephone: 1.203.881.1032, extension 103**  
**Telefacsimile: 1.203.881.1192**  
**e-mail: tsoriano@docro.com**

Tom Soriano has been involved with the discovery, development, clinical evaluation, and commercialization of “standard of care” diagnostic biomarkers for more than twenty years. He has worked to improve the diagnosis, prognosis, and monitoring of patients afflicted with atherosclerosis, infectious diseases (including HIV, STD’s, and Lyme Disease), obstetric and gynecologic maladies, and most prominently, those with solid and hematologic cancers. During the early 80’s, he worked on an Army contract developing self-enclosed immunoassay systems for battlefield detection of biological warfare agents.

From 1988-1996, Tom was employed by DIANON Systems, Inc. and served with great distinction in a variety of positions in DIANON’s R&D Department - all related to the discovery, development, clinical evaluation, and commercialization of new diagnostic biomarker technologies. Tom’s group was responsible for DIANON’s introduction of virtually all of the USA’s “standard of care” oncology biomarker assays. Amongst their numerous successes at DIANON, Tom and his colleagues are inventors of five key clinical utility patents for the use of Free PSA and Total PSA.

In 1996, Tom and his colleagues addressed the market opportunity for a specialized contract research organization (CRO) focused on meeting the needs of the medical *in vitro* diagnostics (IVD) industry and the allied fields of pharmaceuticals and biotech that use IVD products. Today, DOCRO is the leading CRO specializing in the commercialization of biomarker technologies emerging from proteomic and genomic discovery efforts. He is the President and Chief Executive Officer of DOCRO.

Since 1996, DOCRO has been party to more than one hundred and twenty (120) successful 510k, PMA, and PLA IVD submissions to FDA.

Tom holds a degree in Biochemistry and another degree in Psychology from Cornell University, as well as a certificate in finance from Boston University.